stackBETA

Daily

  • Log

Verify

  • Cabinet · stacks
  • Vials · inventory

Build

  • Reconstitution

Plan

  • Can I get it?
  • Compare
  • Synergy check

Learn

  • Encyclopedia
  • Common stacks
  • Pulse
  • Methodology

Info

  • Partners & programs

Stack · v0.1 beta

stackBETAv0.1
LogEncyclopediaPulse
MethodologyPartners & programs
← Back to your stack
Monograph
FDA APPROVEDP-063
Aesthetics

EGF (Epidermal Growth Factor)

53-aa polypeptide binding EGFR → MAPK signaling → keratinocyte + fibroblast proliferation + wound-healing acceleration. Topical formulations dominate the cosmetic-dermatology market; injectable use exists in regenerative medicine.

EmergingAesthetics
Typical doseTopical: 5-50 ppm in serum
Frequencytwice daily, topical
Half-life1h
Citations indexed89
100%50%0%01h2h3h4h5ht½ 1hPK · plasma

How it clearsHalf cleared in ~1h. Most (~96%) gone by ~5h.

DeliveryInjectable
Half-life~1h
EvidenceEmerging
Citations89
Similar compounds
Stack Pro · compare side-by-side

Compare these compounds

Mechanism, evidence, legal path, cost — all side-by-side.

→
Synergy checkCompareReconstitution calc
Mechanism

Cohen + Levi-Montalcini Nobel 1986 work. FDA approval exists for the recombinant version (rhEGF) in diabetic foot ulcers (Regen-D, KGF/Easyef). Cosmetic-dermatology trial body covers wound healing + post-procedure (post-laser, post-microneedling) acceleration. Bryan Johnson's Blueprint Serum lists EGF as one of 8 biomimetic peptides in the formulation. Topical formulations vary widely in actual EGF content + delivery efficacy.

Specifics
Skin tone & textureSkin agingSlow wound healing
Caveats

Topical EGF content varies hugely between products — cosmetic formulations often contain trace levels that may not reach functional skin layers. Injectable use for cosmetic indications is off-label + lacks RCT validation. Theoretical concern for accelerating subclinical malignancy via EGFR pathway upregulation — avoid in patients with skin-cancer history.

Evidence levelEmerging
Regulatory statusFDA approved (rhEGF for diabetic ulcer) · cosmetic-tier topical formulations legal · injectable cosmetic use is grey
DNA / pharmacogenomicsLow — EGFR + downstream MAPK pathway polymorphisms theoretically modulate response; PG not actionable.
Your data · empty

Upload your data to see how it relates to EGF.

Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.

Upload in /history→
Claims & evidence

Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.

  • CLimited evidence

    EGF (Epidermal Growth Factor) — primary mechanism: 53-aa polypeptide binding egfr → mapk signaling → keratinocyte + fibroblast proliferation + wound-healing acceleration. topical formulations dominate the cosmetic-dermatology market; injectable use exists in regenerative medicine.

    2 supporting referencesVerified 13d ago
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    REVIEWFunding undisclosedVerified 13d ago
    PubMed — EGF wound healing trials
  • PubMedEN
    REVIEWFunding undisclosedVerified 13d ago
    PubMed — rhEGF diabetic foot ulcer RCT
FDA APPROVEDP-063

FDA approved (rhEGF for diabetic ulcer) · cosmetic-tier topical formulations legal · injectable cosmetic use is grey

Can I get it? →
Reconstitution calculatorEGF

Pre-filled with this compound's published dose range: Topical: 5-50 ppm in serum · twice daily, topical

Concentration2.50 mg/mL
Draw volume0.100 mL
Insulin syringe10.0 u
Doses per vial20
U-100 syringe — fill to indicatorU-100 · 1 mL
0u25u50u75u100u

Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.

No field reports yet

Field reports are added as users share their real-world protocols.

EGFTopical: 5-50 ppm in serum · twice daily, topical

Next visit & citations

Handoff & sources

Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.

Open Dr PassportMethodologyResearch tableClinician primer
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesPartners & programsWho Stack is forFor creatorsFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.
TodayLibrary
ToolsMe